Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer Schering to Distribute Bioton's Insulin

publication date: Jul 10, 2009

Bayer Schering Pharma has obtained the rights to distribute insulin in China from Polish biotech Bioton. Bayer paid 31 million euros ($43.5 million) upfront for 15-year rights to Bioton’s insulin, in a deal expected to generate between $1.5 billion and $2 billion of sales over the length of the contract. Analysts opined that Bioton’s margins would be between 20% and 30% on the product. More details...

Stock Symbol: (Xetra: BAYG.DE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital